

John M Kane

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3654456/publications.pdf>

Version: 2024-02-01

258
papers

24,262
citations

14655

66
h-index

8630

146
g-index

278
all docs

278
docs citations

278
times ranked

14681
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and safety/tolerability of antipsychotics in the treatment of adult patients with major depressive disorder: a systematic review and meta-analysis. <i>Psychological Medicine</i> , 2023, 53, 4064-4082.	4.5	9
2	Relapse prevention through health technology program reduces hospitalization in schizophrenia. <i>Psychological Medicine</i> , 2023, 53, 4114-4120.	4.5	3
3	Changes in telepsychiatry regulations during the COVID-19 pandemic: 17 countries and regions' approaches to an evolving healthcare landscape. <i>Psychological Medicine</i> , 2022, 52, 2606-2613.	4.5	72
4	Development of a computerized adaptive diagnostic screening tool for psychosis. <i>Schizophrenia Research</i> , 2022, 245, 116-121.	2.0	6
5	Striatal functional connectivity in psychosis relapse: A hypothesis generating study. <i>Schizophrenia Research</i> , 2022, 243, 342-348.	2.0	9
6	Core clinical manifestations of clozapine-related DRESS syndrome: A network analysis. <i>Schizophrenia Research</i> , 2022, 243, 451-453.	2.0	5
7	Predictors of Lack of Relapse After Random Discontinuation of Oral and Long-acting Injectable Antipsychotics in Clinically Stabilized Patients with Schizophrenia: A Re-analysis of Individual Participant Data. <i>Schizophrenia Bulletin</i> , 2022, 48, 296-306.	4.3	21
8	Physical and mental health impact of COVID-19 on children, adolescents, and their families: The Collaborative Outcomes study on Health and Functioning during Infection Times - Children and Adolescents (COH-FIT-C&A). <i>Journal of Affective Disorders</i> , 2022, 299, 367-376.	4.1	33
9	Prevalence of impaired kidney function in patients with long-term lithium treatment: A systematic review and meta-analysis. <i>Bipolar Disorders</i> , 2022, 24, 264-274.	1.9	24
10	Acoustic and Facial Features From Clinical Interviews for Machine Learning-Based Psychiatric Diagnosis: Algorithm Development. <i>JMIR Mental Health</i> , 2022, 9, e24699.	3.3	12
11	Digital and Mobile Health Technology in Collaborative Behavioral Health Care: Scoping Review. <i>JMIR Mental Health</i> , 2022, 9, e30810.	3.3	9
12	Psychotropic Medication Use Is Associated With Greater 1-Year Incidence of Dementia After COVID-19 Hospitalization. <i>Frontiers in Medicine</i> , 2022, 9, 841326.	2.6	7
13	An international clozapine titration guideline to increase its safety and move forward on the route started by German-speaking psychiatrists in the 1960s. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2022, 272, 537-540.	3.2	6
14	Post-acute college student satisfaction with telepsychiatry during the COVID-19 pandemic. <i>Journal of Psychiatric Research</i> , 2022, 151, 1-7.	3.1	5
15	An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels. <i>Pharmacopsychiatry</i> , 2022, 55, 73-86.	3.3	107
16	Pharmacovigilance approaches to study rare and very rare side-effects: the example of clozapine-related DiHS/DRESS syndrome. <i>Expert Opinion on Drug Safety</i> , 2022, 21, 585-587.	2.4	4
17	Digital Strategies to Accelerate Help-Seeking in Youth With Psychiatric Concerns in New York State. <i>Frontiers in Psychiatry</i> , 2022, 13, .	2.6	2
18	Screening the European pharmacovigilance database for reports of clozapine-related DRESS syndrome: 47 novel cases. <i>European Neuropsychopharmacology</i> , 2022, 60, 25-37.	0.7	14

#	ARTICLE	IF	CITATIONS
19	The pharmacological treatment of schizophrenia: How far have we come?. , 2022, 1, .		2
20	Counterpoint. Early intervention for psychosis risk syndromes: Minimizing risk and maximizing benefit. Schizophrenia Research, 2021, 227, 10-17.	2.0	28
21	Development and Validation of a Computerized Adaptive Assessment Tool for Discrimination and Measurement of Psychotic Symptoms. Schizophrenia Bulletin, 2021, 47, 644-652.	4.3	11
22	Post-Marketing Safety Concerns with Esketamine: A Disproportionality Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System. Psychotherapy and Psychosomatics, 2021, 90, 41-48.	8.8	63
23	Adoption of Digital Health Technologies in the Practice of Behavioral Health: Qualitative Case Study of Glucose Monitoring Technology. Journal of Medical Internet Research, 2021, 23, e18119.	4.3	6
24	Towards a framework to develop neuroimaging biomarkers of relapse in schizophrenia. Behavioural Brain Research, 2021, 402, 113099.	2.2	7
25	Antipsychotic Medications: Enhancing Use to Improve Outcomes. Schizophrenia Bulletin, 2021, 47, 1201-1204.	4.3	2
26	A Social Media Study on Mental Health Status Transitions Surrounding Psychiatric Hospitalizations. Proceedings of the ACM on Human-Computer Interaction, 2021, 5, 1-32.	3.3	7
27	Authorsâ€™ Reply to Suhas et al.: Comment on: â€œElevated Clozapine Concentrations in Clozapine-Treated Patients with Hypersalivationâ€ Clinical Pharmacokinetics, 2021, 60, 1077-1079.	3.5	0
28	Assessment of the Impact of Tardive Dyskinesia in Clinical Practice: Consensus Panel Recommendations. Neuropsychiatric Disease and Treatment, 2021, Volume 17, 1589-1597.	2.2	11
29	Unravelling cases of clozapine-related Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) in patients reported otherwise: A systematic review. Journal of Psychopharmacology, 2021, 35, 1062-1073.	4.0	14
30	Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and preâ€“post studies. Lancet Psychiatry, the, 2021, 8, 387-404.	7.4	160
31	Safety and tolerability of lumateperone for the treatment of schizophrenia: a pooled analysis of late-phase placebo- and active-controlled clinical trials. International Clinical Psychopharmacology, 2021, 36, 244-250.	1.7	16
32	Risk Factors, Incidence, and Outcomes of Neuroleptic Malignant Syndrome on Long-Acting Injectable vs Oral Antipsychotics in a Nationwide Schizophrenia Cohort. Schizophrenia Bulletin, 2021, 47, 1621-1630.	4.3	24
33	mHealth-Assisted Detection of Precursors to Relapse in Schizophrenia. Frontiers in Psychiatry, 2021, 12, 642200.	2.6	8
34	Psychoeducation for Inpatients With First-Episode Psychosis: Results From a Survey of Psychiatry Trainees in New York City. Psychiatric Services, 2021, 72, 582-585.	2.0	1
35	Music in behavioral health. , 2021, , .		0
36	Mental Health Care Providersâ€™ Attitudes Toward Telepsychiatry: A Systemwide, Multisite Survey During the COVID-19 Pandemic. Psychiatric Services, 2021, 72, 704-707.	2.0	66

#	ARTICLE	IF	CITATIONS
37	Long-term Continuity of Antipsychotic Treatment for Schizophrenia: A Nationwide Study. <i>Schizophrenia Bulletin</i> , 2021, 47, 1611-1620.	4.3	33
38	Clozapine Management in Schizophrenia Inpatients: A 5-Year Prospective Observational Study of Its Safety and Tolerability Profile. <i>Neuropsychiatric Disease and Treatment</i> , 2021, Volume 17, 2141-2150.	2.2	4
39	Long-acting injectable versus oral antipsychotics for schizophrenia – Authors' reply. <i>Lancet Psychiatry</i> , 2021, 8, 567.	7.4	2
40	Long-acting antipsychotics: is what we know really so? – Authors' reply. <i>Lancet Psychiatry</i> , 2021, 8, 651-652.	7.4	0
41	A systematic review and pooled, patient-level analysis of predictors of mortality in neuroleptic malignant syndrome. <i>Acta Psychiatrica Scandinavica</i> , 2021, 144, 329-341.	4.5	27
42	Utilizing Instagram Data to Identify Usage Patterns Associated With Schizophrenia Spectrum Disorders. <i>Frontiers in Psychiatry</i> , 2021, 12, 691327.	2.6	12
43	Examining Side Effect Variability of Antipsychotic Treatment in Schizophrenia Spectrum Disorders: A Meta-analysis of Variance. <i>Schizophrenia Bulletin</i> , 2021, 47, 1601-1610.	4.3	6
44	Matrix Metalloproteinase 9 Blood Alterations in Patients With Schizophrenia Spectrum Disorders: A Systematic Review and Meta-Analysis. <i>Schizophrenia Bulletin</i> , 2021, 47, 986-996.	4.3	9
45	Elevated Clozapine Concentrations in Clozapine-Treated Patients with Hypersalivation. <i>Clinical Pharmacokinetics</i> , 2021, 60, 329-335.	3.5	20
46	Controversies Surrounding the Use of Long-Acting Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia. <i>CNS Drugs</i> , 2021, 35, 1189-1205.	5.9	32
47	Internet Search Activity of Young People With Mood Disorders Who Are Hospitalized for Suicidal Thoughts and Behaviors: Qualitative Study of Google Search Activity. <i>JMIR Mental Health</i> , 2021, 8, e28262.	3.3	2
48	Awareness of illness moderates self-assessment of psychotic symptoms. <i>Australian and New Zealand Journal of Psychiatry</i> , 2021, , 000486742110574.	2.3	1
49	How to Make an Effective Offer of Clozapine. <i>Journal of Clinical Psychiatry</i> , 2021, 83, .	2.2	3
50	Long-Acting Injectable Antipsychotic Treatment in Schizophrenia and Co-occurring Substance Use Disorders: A Systematic Review. <i>Frontiers in Psychiatry</i> , 2021, 12, 808002.	2.6	14
51	Reply to the Comments by Doherty et al.. <i>Psychotherapy and Psychosomatics</i> , 2021, 90, 140-141.	8.8	1
52	Psychosis breakthrough on antipsychotic maintenance: results from a nationwide study. <i>Psychological Medicine</i> , 2020, 50, 1356-1367.	4.5	26
53	Efficacy and safety of blonanserin transdermal patch in patients with schizophrenia: A 6-week randomized, double-blind, placebo-controlled, multicenter study. <i>Schizophrenia Research</i> , 2020, 215, 408-415.	2.0	31
54	Ranking Antipsychotics for Efficacy and Safety in Schizophrenia. <i>JAMA Psychiatry</i> , 2020, 77, 225.	11.0	14

#	ARTICLE	IF	CITATIONS
55	Predicting relapse with residual symptoms in schizophrenia: A secondary analysis of the PROACTIVE trial. <i>Schizophrenia Research</i> , 2020, 215, 173-180.	2.0	7
56	Google search activity in early psychosis: A qualitative analysis of internet search query content in first episode psychosis. <i>Microbial Biotechnology</i> , 2020, 14, 606-612.	1.7	8
57	Dose and safety concerns of clozapine: Worldwide package inserts need revisions. <i>Schizophrenia Research</i> , 2020, 216, 2-4.	2.0	16
58	The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research. <i>NPJ Schizophrenia</i> , 2020, 6, 1.	3.6	193
59	Predictors of psychosis breakthrough during 24 months of long-acting antipsychotic maintenance treatment in first episode schizophrenia. <i>Schizophrenia Research</i> , 2020, 225, 55-62.	2.0	23
60	Focused Ethnographic Examination of Barriers to Use of Long-Acting Injectable Antipsychotics. <i>Psychiatric Services</i> , 2020, 71, 337-342.	2.0	8
61	Incentivizing Is Not Coercing: A Commentary. <i>Psychiatric Services</i> , 2020, 71, 301-302.	2.0	6
62	Psychosis relapse during treatment with long-acting injectable antipsychotics in individuals with schizophrenia-spectrum disorders: an individual participant data meta-analysis. <i>Lancet Psychiatry</i> , the, 2020, 7, 749-761.	7.4	66
63	Effect of Long-Acting Injectable Antipsychotics vs Usual Care on Time to First Hospitalization in Early-Phase Schizophrenia. <i>JAMA Psychiatry</i> , 2020, 77, 1217.	11.0	107
64	Do Asian Patients Require Only Half of the Clozapine Dose Prescribed for Caucasians? A Critical Overview. <i>Indian Journal of Psychological Medicine</i> , 2020, 42, 4-10.	1.5	61
65	Expanding phenomenologic heterogeneity of tardive syndromes: Time for an updated assessment tool. <i>Parkinsonism and Related Disorders</i> , 2020, 77, 141-145.	2.2	4
66	Natural History, Not Lead Time: Response to Srihari et al.. <i>American Journal of Psychiatry</i> , 2020, 177, 1185-1186.	7.2	2
67	T205. LUMATEPERONE IN THE TREATMENT OF SCHIZOPHRENIA: EVALUATION OF EXTRAPYRAMIDAL AND MOTOR SYMPTOMS IN 4 LATE-PHASE CLINICAL TRIALS. <i>Schizophrenia Bulletin</i> , 2020, 46, S310-S310.	4.3	1
68	Smartphone relapse prediction in serious mental illness: a pathway towards personalized preventive care. <i>World Psychiatry</i> , 2020, 19, 308-309.	10.4	22
69	Adding Oral Contraceptives to Clozapine May Require Halving the Clozapine Dose. <i>Journal of Clinical Psychopharmacology</i> , 2020, 40, 308-310.	1.4	16
70	The physical health and side-effect monitoring of patients prescribed clozapine: data from a clinical audit conducted in UK mental health services. <i>Therapeutic Advances in Psychopharmacology</i> , 2020, 10, 204512532093790.	2.7	6
71	Edentulousness in severely mentally ill patients: A pilot study of sex-specific patterns for risk factors including the glutathione S-transferase M1 gene. <i>Schizophrenia Research</i> , 2020, 224, 178-179.	2.0	0
72	Identifying signals associated with psychiatric illness utilizing language and images posted to Facebook. <i>NPJ Schizophrenia</i> , 2020, 6, 38.	3.6	22

#	ARTICLE	IF	CITATIONS
73	Lead-Time Bias as a Potential Explanation for the Link Between Duration of Untreated Psychosis and Outcome: Response to Iyer et al.. American Journal of Psychiatry, 2020, 177, 1181-1183.	7.2	2
74	Duration of Untreated Psychosis: Getting Both the Timing and the Sample Right: Response to Woods et al.. American Journal of Psychiatry, 2020, 177, 1183-1185.	7.2	4
75	Consensus statement on the use of clozapine during the COVID-19 pandemic. Journal of Psychiatry and Neuroscience, 2020, 45, 222-223.	2.4	102
76	Clozapine and COVID-19: The authors respond. Journal of Psychiatry and Neuroscience, 2020, 45, E1-E2.	2.4	1
77	There is a non-evidence-based app for that: A systematic review and mixed methods analysis of depression- and anxiety-related apps that incorporate unrecognized techniques. Journal of Affective Disorders, 2020, 273, 410-421.	4.1	37
78	The value of early intervention in creating the new mental health system: Response to Allison et al. Australian and New Zealand Journal of Psychiatry, 2020, 54, 667-669.	2.3	6
79	Prolactin changes during electroconvulsive therapy: A systematic review and meta-analysis. Journal of Psychiatric Research, 2020, 128, 25-32.	3.1	2
80	185 The Safety and Tolerability of Lumateperone 42 mg for the Treatment of Schizophrenia: A Pooled Analysis of 3 Randomized Placebo-Controlled Trials. CNS Spectrums, 2020, 25, 316-317.	1.2	2
81	Clozapine-related drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: a systematic review. Expert Review of Clinical Pharmacology, 2020, 13, 875-883.	3.1	26
82	Using therapeutic drug monitoring to personalize clozapine dosing in Asians. Asia-Pacific Psychiatry, 2020, 12, e12384.	2.2	29
83	Lack of ECT effects on clozapine plasma levels in patients with treatment-resistant schizophrenia: Pharmacokinetic evidence from a randomized clinical trial. Schizophrenia Research, 2020, 218, 309-311.	2.0	1
84	Lead-Time Bias Confounds Association Between Duration of Untreated Psychosis and Illness Course in Schizophrenia. American Journal of Psychiatry, 2020, 177, 327-334.	7.2	49
85	Cultural Influences in Psychiatry—Reply. JAMA - Journal of the American Medical Association, 2020, 323, 1193.	7.4	0
86	Iron homeostasis alterations and risk for akathisia in patients treated with antipsychotics: A systematic review and meta-analysis of cross-sectional studies. European Neuropsychopharmacology, 2020, 35, 1-11.	0.7	12
87	The Neurobiology of Treatment-Resistant Schizophrenia: Paths to Antipsychotic Resistance and A Roadmap for Future Research. Focus (American Psychiatric Publishing), 2020, 18, 456-465.	0.8	8
88	Utilizing Machine Learning on Internet Search Activity to Support the Diagnostic Process and Relapse Detection in Young Individuals With Early Psychosis: Feasibility Study. JMIR Mental Health, 2020, 7, e19348.	3.3	10
89	Predicting Early Warning Signs of Psychotic Relapse From Passive Sensing Data: An Approach Using Encoder-Decoder Neural Networks. JMIR MHealth and UHealth, 2020, 8, e19962.	3.7	58
90	Patient Attitudes Toward Telepsychiatry During the COVID-19 Pandemic: A Nationwide, Multisite Survey. JMIR Mental Health, 2020, 7, e24761.	3.3	75

#	ARTICLE	IF	CITATIONS
91	Blood Levels to Optimize Antipsychotic Treatment in Clinical Practice. Journal of Clinical Psychiatry, 2020, 81, .	2.2	86
92	Outcomes of Neuroleptic Malignant Syndrome With Depot Versus Oral Antipsychotics. Journal of Clinical Psychiatry, 2020, 82, .	2.2	15
93	O8.2. VALIDATION OF A COMPUTERIZED ADAPTIVE TESTING TOOL FOR PSYCHOSIS: THE CAT-PSYCHOSIS BATTERY. Schizophrenia Bulletin, 2020, 46, S19-S19.	4.3	0
94	Identifying emerging mental illness utilizing search engine activity: A feasibility study. PLoS ONE, 2020, 15, e0240820.	2.5	6
95	Implementation and fidelity assessment of the NAVIGATE treatment program for first episode psychosis in a multi-site study. Schizophrenia Research, 2019, 204, 271-281.	2.0	31
96	Association With Hospitalization and All-Cause Discontinuation Among Patients With Schizophrenia on Clozapine vs Other Oral Second-Generation Antipsychotics. JAMA Psychiatry, 2019, 76, 1052.	11.0	243
97	A comprehensive review of the clinical utility of and a combined analysis of the clozapine/norclozapine ratio in therapeutic drug monitoring for adult patients. Expert Review of Clinical Pharmacology, 2019, 12, 603-621.	3.1	69
98	Use of Behavioral Economics to Improve Medication Adherence in Severe Mental Illness. Psychiatric Services, 2019, 70, 955-957.	2.0	18
99	Is Transcultural Psychiatry Possible?. JAMA - Journal of the American Medical Association, 2019, 322, 2167.	7.4	18
100	O6.4. GOOGLE SEARCH ACTIVITY IN EARLY PSYCHOSIS: A QUALITATIVE ANALYSIS OF INTERNET SEARCH QUERY CONTENT IN FIRST EPISODE PSYCHOSIS. Schizophrenia Bulletin, 2019, 45, S177-S177.	4.3	2
101	Abnormal involuntary movement scale in tardive dyskinesia: Minimal clinically important difference. Movement Disorders, 2019, 34, 1203-1209.	3.9	18
102	Methodological Gaps in Predicting Mental Health States from Social Media. , 2019, , .		69
103	Evaluation of Differences in Individual Treatment Response in Schizophrenia Spectrum Disorders. JAMA Psychiatry, 2019, 76, 1063.	11.0	48
104	Capturing behavioral indicators of persecutory ideation using mobile technology. Journal of Psychiatric Research, 2019, 116, 112-117.	3.1	27
105	Long-term effectiveness of oral second-generation antipsychotics in patients with schizophrenia and related disorders: a systematic review and meta-analysis of direct head-to-head comparisons. World Psychiatry, 2019, 18, 208-224.	10.4	93
106	Predictors of Hospitalization of Individuals With First-Episode Psychosis: Data From a 2-Year Follow-Up of the RAISE-ETP. Psychiatric Services, 2019, 70, 569-577.	2.0	26
107	Longitudinal associations of family burden and patient quality of life in the context of first-episode schizophrenia in the RAISE-ETP study. Psychiatry Research, 2019, 276, 60-68.	3.3	10
108	Online help-seeking prior to diagnosis: Can web-based resources reduce the duration of untreated mood disorders in young people?. Journal of Affective Disorders, 2019, 252, 130-134.	4.1	18

#	ARTICLE	IF	CITATIONS
109	Relationships between smartphone social behavior and relapse in schizophrenia: A preliminary report. <i>Schizophrenia Research</i> , 2019, 208, 167-172.	2.0	67
110	Structural similarity networks predict clinical outcome in early-phase psychosis. <i>Neuropsychopharmacology</i> , 2019, 44, 915-922.	5.4	23
111	Clinical Guidance on the Identification and Management of Treatment-Resistant Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2019, 80, .	2.2	157
112	Clinically Significant Drug-Drug Interactions with Agents for Attention-Deficit/Hyperactivity Disorder. <i>CNS Drugs</i> , 2019, 33, 1201-1222.	5.9	19
113	Low Incidence of Neuroleptic Malignant Syndrome Associated With Paliperidone Palmitate Long-Acting Injectable. <i>Journal of Clinical Psychopharmacology</i> , 2019, 39, 180-182.	1.4	10
114	Is there a trial bias impacting user engagement with unguided e-mental health interventions? A systematic comparison of published reports and real-world usage of the same programs. <i>Translational Behavioral Medicine</i> , 2019, 9, 1020-1033.	2.4	56
115	Off-hours use of a smartphone intervention to extend support for individuals with schizophrenia spectrum disorders recently discharged from a psychiatric hospital. <i>Schizophrenia Research</i> , 2019, 206, 200-208.	2.0	24
116	Schizophrenia Polygenic Risk Score as a Predictor of Antipsychotic Efficacy in First-Episode Psychosis. <i>American Journal of Psychiatry</i> , 2019, 176, 21-28.	7.2	127
117	Characterization of psychiatrically hospitalized college students. <i>Journal of American College Health</i> , 2019, 67, 654-660.	1.5	6
118	Objective User Engagement With Mental Health Apps: Systematic Search and Panel-Based Usage Analysis. <i>Journal of Medical Internet Research</i> , 2019, 21, e14567.	4.3	479
119	Patients With Early-Phase Schizophrenia Will Accept Treatment With Sustained-Release Medication (Long-Acting Injectable Antipsychotics). <i>Journal of Clinical Psychiatry</i> , 2019, 80, .	2.2	35
120	Clinical risk factors for the development of tardive dyskinesia. <i>Journal of the Neurological Sciences</i> , 2018, 389, 21-27.	0.6	89
121	Summary of Key Issues Raised in the Technology for Early Awareness of Addiction and Mental Illness (TEAAM-I) Meeting. <i>Psychiatric Services</i> , 2018, 69, 590-592.	2.0	8
122	Comparison of Early Intervention Services vs Treatment as Usual for Early-Phase Psychosis. <i>JAMA Psychiatry</i> , 2018, 75, 555.	11.0	516
123	Factor structure of therapist fidelity to individual resiliency training in the Recovery After an Initial Schizophrenia Episode Early Treatment Program. <i>Microbial Biotechnology</i> , 2018, 12, 1052-1063.	1.7	4
124	Demographic and clinical correlates of substance use disorders in first episode psychosis. <i>Schizophrenia Research</i> , 2018, 194, 4-12.	2.0	65
125	Effectiveness of Long-Acting Injectable vs Oral Antipsychotics in Patients With Schizophrenia: A Meta-analysis of Prospective and Retrospective Cohort Studies. <i>Schizophrenia Bulletin</i> , 2018, 44, 603-619.	4.3	137
126	Predicting relapse in schizophrenia: Is BDNF a plausible biological marker?. <i>Schizophrenia Research</i> , 2018, 193, 263-268.	2.0	18

#	ARTICLE	IF	CITATIONS
127	Demographic, psychosocial, clinical, and neurocognitive baseline characteristics of Black Americans in the RAISE-ETP study. <i>Schizophrenia Research</i> , 2018, 193, 64-68.	2.0	24
128	Prospective Relationships Between Motivation and Functioning in Recovery After a First Episode of Schizophrenia. <i>Schizophrenia Bulletin</i> , 2018, 44, 369-377.	4.3	31
129	Psychopharmacological Treatment in the RAISE-ETP Study: Outcomes of a Manual and Computer Decision Support System Based Intervention. <i>American Journal of Psychiatry</i> , 2018, 175, 169-179.	7.2	46
130	Accounting for group differences in study retention in a randomized trial of specialized treatment for first episode psychosis. <i>Schizophrenia Research</i> , 2018, 195, 481-487.	2.0	6
131	A randomized, double-blind, placebo-controlled proof of concept study to evaluate samidorphan in the prevention of olanzapine-induced weight gain in healthy volunteers. <i>Schizophrenia Research</i> , 2018, 195, 245-251.	2.0	42
132	Predictors of aggression in 3,322 patients with affective disorders and schizophrenia spectrum disorders evaluated in an emergency department setting. <i>Schizophrenia Research</i> , 2018, 195, 136-141.	2.0	12
133	Digital Trajectories to Care in First-Episode Psychosis. <i>Psychiatric Services</i> , 2018, 69, 1259-1263.	2.0	31
134	Disturbing Lack of Early Intervention Studies in Bipolar Disorder—Reply. <i>JAMA Psychiatry</i> , 2018, 75, 1202.	11.0	0
135	Tardive dyskinesia risk with first- and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis. <i>World Psychiatry</i> , 2018, 17, 330-340.	10.4	117
136	Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 1215-1238.	4.3	51
137	What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia?. <i>World Psychiatry</i> , 2018, 17, 149-160.	10.4	188
138	Identifying patients and clinical scenarios for use of long-acting injectable antipsychotics – expert consensus survey part 1. <i>Neuropsychiatric Disease and Treatment</i> , 2018, Volume 14, 1463-1474.	2.2	26
139	A meta-analysis of factors associated with quality of life in first episode psychosis. <i>Schizophrenia Research</i> , 2018, 202, 26-36.	2.0	65
140	Initiating/maintaining long-acting injectable antipsychotics in schizophrenia/schizoaffective or bipolar disorder – expert consensus survey part 2. <i>Neuropsychiatric Disease and Treatment</i> , 2018, Volume 14, 1475-1492.	2.2	21
141	Examining Predictors of Real-World User Engagement with Self-Guided eHealth Interventions: Analysis of Mobile Apps and Websites Using a Novel Dataset. <i>Journal of Medical Internet Research</i> , 2018, 20, e11491.	4.3	91
142	Digital Peer-Support Platform (7Cups) as an Adjunct Treatment for Women With Postpartum Depression: Feasibility, Acceptability, and Preliminary Efficacy Study. <i>JMIR MHealth and UHealth</i> , 2018, 6, e38.	3.7	64
143	Revisiting the Abnormal Involuntary Movement Scale. <i>Journal of Clinical Psychiatry</i> , 2018, 79, .	2.2	32
144	Role of social media and the internet in pathways to care for adolescents and young adults with psychotic disorders and non-psychotic mood disorders. <i>Microbial Biotechnology</i> , 2017, 11, 290-295.	1.7	124

#	ARTICLE	IF	CITATIONS
145	Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis. <i>World Psychiatry</i> , 2017, 16, 77-89.	10.4	156
146	Home-Based Outpatient Telepsychiatry to Improve Adherence With Treatment Appointments: A Pilot Study. <i>Psychiatric Services</i> , 2017, 68, 743-746.	2.0	20
147	Incomes and Outcomes: Social Security Disability Benefits in First-Episode Psychosis. <i>American Journal of Psychiatry</i> , 2017, 174, 886-894.	7.2	31
148	Efficacy of 42 Pharmacologic Cotreatment Strategies Added to Antipsychotic Monotherapy in Schizophrenia. <i>JAMA Psychiatry</i> , 2017, 74, 675.	11.0	153
149	Ω-3 Polyunsaturated Fatty Acids to Prevent Psychosis. <i>JAMA Psychiatry</i> , 2017, 74, 11.	11.0	12
150	CrossCheck: Integrating self-report, behavioral sensing, and smartphone use to identify digital indicators of psychotic relapse. <i>Psychiatric Rehabilitation Journal</i> , 2017, 40, 266-275.	1.1	131
151	Accuracy of Clinician Assessments of Medication Status in the Emergency Setting. <i>Journal of Clinical Psychopharmacology</i> , 2017, 37, 310-314.	1.4	29
152	Relationship between Duration of Untreated Psychosis and Intrinsic Corticostriatal Connectivity in Patients with Early Phase Schizophrenia. <i>Neuropsychopharmacology</i> , 2017, 42, 2214-2221.	5.4	55
153	Psychological well-being and mental health recovery in the NIMH RAISE early treatment program. <i>Schizophrenia Research</i> , 2017, 185, 167-172.	2.0	29
154	Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology. <i>American Journal of Psychiatry</i> , 2017, 174, 216-229.	7.2	685
155	Clozapine Reduces All-Cause Mortality. <i>American Journal of Psychiatry</i> , 2017, 174, 920-921.	7.2	7
156	Predicting Symptom Trajectories of Schizophrenia using Mobile Sensing. , 2017, 1, 1-24.		63
157	Psychosis breakthrough on antipsychotic maintenance medication (BAMM): what can we learn?. <i>NPJ Schizophrenia</i> , 2017, 3, 36.	3.6	14
158	Improving outcomes of first-episode psychosis: an overview. <i>World Psychiatry</i> , 2017, 16, 251-265.	10.4	363
159	Using Digital Media Advertising in Early Psychosis Intervention. <i>Psychiatric Services</i> , 2017, 68, 1144-1149.	2.0	38
160	Supported employment and education in comprehensive, integrated care for first episode psychosis: Effects on work, school, and disability income. <i>Schizophrenia Research</i> , 2017, 182, 120-128.	2.0	74
161	Linguistic Markers Indicating Therapeutic Outcomes of Social Media Disclosures of Schizophrenia. <i>Proceedings of the ACM on Human-Computer Interaction</i> , 2017, 1, 1-27.	3.3	57
162	Enlight: A Comprehensive Quality and Therapeutic Potential Evaluation Tool for Mobile and Web-Based eHealth Interventions. <i>Journal of Medical Internet Research</i> , 2017, 19, e82.	4.3	157

#	ARTICLE	IF	CITATIONS
163	A Collaborative Approach to Identifying Social Media Markers of Schizophrenia by Employing Machine Learning and Clinical Appraisals. <i>Journal of Medical Internet Research</i> , 2017, 19, e289.	4.3	119
164	Analyzing mHealth Engagement: Joint Models for Intensively Collected User Engagement Data. <i>JMIR MHealth and UHealth</i> , 2017, 5, e1.	3.7	60
165	Neuropsychological Test Performance to Enhance Identification of Subjects at Clinical High Risk for Psychosis and Be Most Promising for Predictive Algorithms for Conversion to Psychosis. <i>Journal of Clinical Psychiatry</i> , 2017, 78, e28-e40.	2.2	68
166	Dr Correll and Colleagues Reply. <i>Journal of Clinical Psychiatry</i> , 2017, 78, e1062.	2.2	1
167	Baseline Characteristics and Early Response at Week 1 Predict Treatment Outcome in Adolescents With Bipolar Manic or Mixed Episode Treated With Olanzapine. <i>Journal of Clinical Psychiatry</i> , 2017, 78, e1158-e1166.	2.2	6
168	Tardive Dyskinesia Prevalence in the Period of Second-Generation Antipsychotic Use. <i>Journal of Clinical Psychiatry</i> , 2017, 78, e264-e278.	2.2	179
169	Technology-Assisted Parent Training Programs for Children and Adolescents With Disruptive Behaviors. <i>Journal of Clinical Psychiatry</i> , 2017, 78, e957-e969.	2.2	45
170	Epidemiology, Prevention, and Assessment of Tardive Dyskinesia and Advances in Treatment. <i>Journal of Clinical Psychiatry</i> , 2017, 78, 1136-1147.	2.2	58
171	Assessing Patients for Tardive Dyskinesia. <i>Journal of Clinical Psychiatry</i> , 2017, 78, e1428.	2.2	2
172	Long-Term Safety and Tolerability of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia and a Diagnosis of Schizophrenia or Mood Disorder. <i>Psychopharmacology Bulletin</i> , 2017, 47, 61-68.	0.0	13
173	Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder. <i>Psychopharmacology Bulletin</i> , 2017, 47, 69-76.	0.0	14
174	Impact of online resources and social media on help-seeking behaviour in youth with psychotic symptoms. <i>Microbial Biotechnology</i> , 2016, 10, 397-403.	1.7	25
175	Variants in the DRD2 locus and antipsychotic-related prolactin levels: A meta-analysis. <i>Psychoneuroendocrinology</i> , 2016, 72, 1-10.	2.7	31
176	CrossCheck. , 2016, , .		183
177	Digital Parent Training for Children with Disruptive Behaviors: Systematic Review and Meta-Analysis of Randomized Trials. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2016, 26, 740-749.	1.3	88
178	Pharmacogenetic Associations of Antipsychotic Drug-Related Weight Gain: A Systematic Review and Meta-analysis. <i>Schizophrenia Bulletin</i> , 2016, 42, 1418-1437.	4.3	149
179	Comparison of Injectable and Oral Antipsychotics in Relapse Rates in a Pragmatic 30-Month Schizophrenia Relapse Prevention Study. <i>Psychiatric Services</i> , 2016, 67, 1370-1372.	2.0	8
180	Safety and tolerability of long-acting injectable versus oral antipsychotics: A meta-analysis of randomized controlled studies comparing the same antipsychotics. <i>Schizophrenia Research</i> , 2016, 176, 220-230.	2.0	97

#	ARTICLE	IF	CITATIONS
181	Health Technology Intervention After Hospitalization for Schizophrenia: Service Utilization and User Satisfaction. <i>Psychiatric Services</i> , 2016, 67, 1035-1038.	2.0	23
182	Activating and Tranquilizing Effects of First-Time Treatment with Aripiprazole, Olanzapine, Quetiapine, and Risperidone in Youth. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2016, 26, 458-470.	1.3	20
183	Response to Amos: Addressing Purported Methodological Flaws in RAISE-ETP Results. <i>American Journal of Psychiatry</i> , 2016, 173, 535-536.	7.2	2
184	The Role of Clozapine in Treatment-Resistant Schizophrenia. <i>JAMA Psychiatry</i> , 2016, 73, 187.	11.0	72
185	Mobile Behavioral Sensing for Outpatients and Inpatients With Schizophrenia. <i>Psychiatric Services</i> , 2016, 67, 558-561.	2.0	175
186	Safety and tolerability of antipsychotic co-treatment in patients with schizophrenia: results from a systematic review and meta-analysis of randomized controlled trials. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 591-612.	2.4	29
187	Attenuated psychotic and basic symptom characteristics in adolescents with ultra-high risk criteria for psychosis, other non-psychotic psychiatric disorders and early-onset psychosis. <i>European Child and Adolescent Psychiatry</i> , 2016, 25, 1091-1102.	4.7	26
188	Coordinated Technology-Delivered Treatment to Prevent Rehospitalization in Schizophrenia: A Novel Model of Care. <i>Psychiatric Services</i> , 2016, 67, 444-447.	2.0	22
189	Comprehensive Versus Usual Community Care for First-Episode Psychosis: 2-Year Outcomes From the NIMH RAISE Early Treatment Program. <i>American Journal of Psychiatry</i> , 2016, 173, 362-372.	7.2	601
190	Baseline Striatal Functional Connectivity as a Predictor of Response to Antipsychotic Drug Treatment. <i>American Journal of Psychiatry</i> , 2016, 173, 69-77.	7.2	168
191	mHealth for Schizophrenia: Patient Engagement With a Mobile Phone Intervention Following Hospital Discharge. <i>JMIR Mental Health</i> , 2016, 3, e34.	3.3	117
192	The Use of Long-Acting Injectable Antipsychotics in Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2016, 77, 1-24.	2.2	267
193	Efficacy for Psychopathology and Body Weight and Safety of Topiramate-Antipsychotic Cotreatment in Patients With Schizophrenia Spectrum Disorders. <i>Journal of Clinical Psychiatry</i> , 2016, 77, e746-e756.	2.2	33
194	Schizophrenia. <i>Nature Reviews Disease Primers</i> , 2015, 1, 15067.	30.5	724
195	Patterns and predictors of medication discrepancies in primary care. <i>Journal of Evaluation in Clinical Practice</i> , 2015, 21, 831-839.	1.8	30
196	Early Improvement As a Predictor of Later Response to Antipsychotics in Schizophrenia: A Diagnostic Test Review. <i>American Journal of Psychiatry</i> , 2015, 172, 617-629.	7.2	150
197	Response to Saraga. <i>American Journal of Psychiatry</i> , 2015, 172, 588-588.	7.2	0
198	Neuromotor Adverse Effects in 342 Youth During 12 Weeks of Naturalistic Treatment With 5 Second-Generation Antipsychotics. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2015, 54, 718-727.e3.	0.5	32

#	ARTICLE	IF	CITATIONS
199	Objective identification and analysis of physiological and behavioral signs of schizophrenia. <i>Journal of Mental Health</i> , 2015, 24, 276-282.	1.9	23
200	Abnormal Resting State fMRI Activity Predicts Processing Speed Deficits in First-Episode Psychosis. <i>Neuropsychopharmacology</i> , 2015, 40, 1631-1639.	5.4	14
201	Antipsychotic Treatment and Functional Connectivity of the Striatum in First-Episode Schizophrenia. <i>JAMA Psychiatry</i> , 2015, 72, 5.	11.0	277
202	Ambiguous findings concerning potential advantages of depot antipsychotics. <i>Current Opinion in Psychiatry</i> , 2015, 28, 216-221.	6.3	47
203	The NAVIGATE Program for First-Episode Psychosis: Rationale, Overview, and Description of Psychosocial Components. <i>Psychiatric Services</i> , 2015, 66, 680-690.	2.0	179
204	Duration of Untreated Psychosis in Community Treatment Settings in the United States. <i>Psychiatric Services</i> , 2015, 66, 753-756.	2.0	100
205	Outcome of Youth with Early-Phase Schizophrenia-Spectrum Disorders and Psychosis Not Otherwise Specified Treated with Second-Generation Antipsychotics: 12 Week Results from a Prospective, Naturalistic Cohort Study. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2015, 25, 535-547.	1.3	8
206	Relationship of Cognition to Clinical Response in First-Episode Schizophrenia Spectrum Disorders. <i>Schizophrenia Bulletin</i> , 2015, 41, 1237-1247.	4.3	45
207	Responses to Tobacco Smoking-Related Health Messages in Young People With Recent-Onset Schizophrenia. <i>Schizophrenia Bulletin</i> , 2015, 41, 1256-1265.	4.3	9
208	A Randomized Comparison of Aripiprazole and Risperidone for the Acute Treatment of First-Episode Schizophrenia and Related Disorders: 3-Month Outcomes. <i>Schizophrenia Bulletin</i> , 2015, 41, 1227-1236.	4.3	100
209	Clozapine in schizophrenia and its association with treatment satisfaction and quality of life: Findings of the three national surveys on use of psychotropic medications in China (2002â€“2012). <i>Schizophrenia Research</i> , 2015, 168, 523-529.	2.0	17
210	Comparison of SGA Oral Medications and a Long-Acting Injectible SGA: The PROACTIVE Study. <i>Schizophrenia Bulletin</i> , 2015, 41, 449-459.	4.3	65
211	Electroconvulsive Therapy Augmentation in Clozapine-Resistant Schizophrenia: A Prospective, Randomized Study. <i>American Journal of Psychiatry</i> , 2015, 172, 52-58.	7.2	274
212	Prescription Practices in the Treatment of First-Episode Schizophrenia Spectrum Disorders: Data From the National RAISE-ETP Study. <i>American Journal of Psychiatry</i> , 2015, 172, 237-248.	7.2	80
213	The Role of NMDA Receptors in Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2015, 76, e01-e01.	2.2	4
214	The RAISE Early Treatment Program for First-Episode Psychosis. <i>Journal of Clinical Psychiatry</i> , 2015, 76, 240-246.	2.2	121
215	White Matter Changes Associated with Antipsychotic Treatment in First-Episode Psychosis. <i>Neuropsychopharmacology</i> , 2014, 39, 1324-1331.	5.4	109
216	Cardiometabolic Risk in Patients With First-Episode Schizophrenia Spectrum Disorders. <i>JAMA Psychiatry</i> , 2014, 71, 1350.	11.0	318

#	ARTICLE	IF	CITATIONS
217	Effects of aripiprazole once-monthly on domains of personal and social performance: Results from 2 multicenter, randomized, double-blind studies. <i>Schizophrenia Research</i> , 2014, 159, 415-420.	2.0	27
218	Long-Acting Injectable vs Oral Antipsychotics for Relapse Prevention in Schizophrenia: A Meta-Analysis of Randomized Trials. <i>Schizophrenia Bulletin</i> , 2014, 40, 192-213.	4.3	332
219	Antidepressants for cognitive impairment in schizophrenia " A systematic review and meta-analysis. <i>Schizophrenia Research</i> , 2014, 159, 385-394.	2.0	48
220	BDNF Val66Met polymorphism and antipsychotic-induced tardive dyskinesia occurrence and severity: A meta-analysis. <i>Schizophrenia Research</i> , 2014, 152, 365-372.	2.0	20
221	Subcortical modulation of attentional control by second-generation antipsychotics in first-episode psychosis. <i>Psychiatry Research - Neuroimaging</i> , 2014, 221, 127-134.	1.8	18
222	Sudden unexpected death in schizophrenia: Autopsy findings in psychiatric inpatients. <i>Schizophrenia Research</i> , 2014, 155, 72-76.	2.0	68
223	Rapid clozapine titration in treatment-refractory bipolar disorder. <i>Journal of Affective Disorders</i> , 2014, 166, 168-172.	4.1	48
224	Attitudinal Barriers to Prescribing LAI Antipsychotics in the Outpatient Setting. <i>Journal of Clinical Psychiatry</i> , 2014, 75, e33-e33.	2.2	10
225	Assessing the comparative effectiveness of long-acting injectable vs. oral antipsychotic medications in the prevention of relapse provides a case study in comparative effectiveness research in psychiatry. <i>Journal of Clinical Epidemiology</i> , 2013, 66, S37-S41.	5.0	109
226	Effectiveness of lurasidone vs. quetiapine XR for relapse prevention in schizophrenia: A 12-month, double-blind, noninferiority study. <i>Schizophrenia Research</i> , 2013, 147, 95-102.	2.0	105
227	Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies. <i>World Psychiatry</i> , 2013, 12, 216-226.	10.4	356
228	Long-Acting Injectable Versus Oral Antipsychotics in Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2013, 74, 957-965.	2.2	371
229	Improving Patient Outcomes in Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2013, 74, e18.	2.2	30
230	Termination of Clozapine Treatment Due to Medical Reasons. <i>Journal of Clinical Psychiatry</i> , 2013, 74, 603-613.	2.2	193
231	Clozapine is underutilized. <i>Shanghai Archives of Psychiatry</i> , 2012, 24, 114-5.	0.7	2
232	Incidence of Tardive Dyskinesia with Risperidone or Olanzapine in the Elderly: Results from a 2-Year, Prospective Study in Antipsychotic-Naïve Patients. <i>Neuropsychopharmacology</i> , 2011, 36, 1738-1746.	5.4	45
233	Efficacy and Safety of Asenapine in a Placebo- and Haloperidol-Controlled Trial in Patients With Acute Exacerbation of Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2010, 30, 106-115.	1.4	104
234	Past and Present Progress in the Pharmacologic Treatment of Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2010, 71, 1115-1124.	2.2	188

#	ARTICLE	IF	CITATIONS
235	Olanzapine Long-Acting Injection: A 24-Week, Randomized, Double-Blind Trial of Maintenance Treatment in Patients With Schizophrenia. <i>American Journal of Psychiatry</i> , 2010, 167, 181-189.	7.2	181
236	Pharmacologic treatment of schizophrenia. <i>Dialogues in Clinical Neuroscience</i> , 2010, 12, 345-357.	3.7	86
237	Clinical guideline recommendations for antipsychotic long-acting injections. <i>British Journal of Psychiatry</i> , 2009, 195, s63-s67.	2.8	118
238	Cognitive deficits in schizophrenia: short-term and long-term. <i>World Psychiatry</i> , 2008, 7, 29-30.	10.4	7
239	Utilization of Long-Acting Antipsychotic Medication in Patient Care. <i>CNS Spectrums</i> , 2006, 11, 1-8.	1.2	29
240	Commentary on the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE). <i>Journal of Clinical Psychiatry</i> , 2006, 67, 831-832.	2.2	32
241	Lower Risk for Tardive Dyskinesia Associated With Second-Generation Antipsychotics: A Systematic Review of 1-Year Studies. <i>American Journal of Psychiatry</i> , 2004, 161, 414-425.	7.2	653
242	Long-Acting Injectable Risperidone: Efficacy and Safety of the First Long-Acting Atypical Antipsychotic. <i>American Journal of Psychiatry</i> , 2003, 160, 1125-1132.	7.2	464
243	Clozapine Treatment for Suicidality in Schizophrenia_{title}International Suicide Prevention Trial (InterSePT)_{title}. <i>Archives of General Psychiatry</i> , 2003, 60, 82.	12.3	1,200
244	Treatment Models and Designs for Intervention Research During the Psychotic Prodrome. <i>Schizophrenia Bulletin</i> , 2003, 29, 747-756.	4.3	17
245	The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. <i>Journal of Clinical Psychiatry</i> , 2003, 64 Suppl 12, 5-19.	2.2	102
246	Strategies for improving compliance in treatment of schizophrenia by using a long-acting formulation of an antipsychotic: clinical studies. <i>Journal of Clinical Psychiatry</i> , 2003, 64 Suppl 16, 34-40.	2.2	19
247	Efficacy and Safety of Aripiprazole and Haloperidol Versus Placebo in Patients With Schizophrenia and Schizoaffective Disorder. <i>Journal of Clinical Psychiatry</i> , 2002, 63, 763-771.	2.2	517
248	Side effects of antipsychotic drugs. <i>Postgraduate Medicine</i> , 2000, 107, 169-178.	2.0	19
249	Olanzapine in the long-term treatment of schizophrenia. <i>British Journal of Psychiatry</i> , 1999, 174, 26-29.	2.8	21
250	Essential Role of Induced Nitric Oxide in the Initiation of the Inflammatory Response after Hemorrhagic Shock. <i>Journal of Experimental Medicine</i> , 1998, 187, 917-928.	8.5	457
251	Prospective Study of Tardive Dyskinesia in the Elderly: Rates and Risk Factors. <i>American Journal of Psychiatry</i> , 1998, 155, 1521-1528.	7.2	213
252	Methylphenidate Response, Psychopathology and Tardive Dyskinesia as Predictors of Relapse in Schizophrenia. <i>Neuropsychopharmacology</i> , 1994, 11, 107-118.	5.4	61

#	ARTICLE	IF	CITATIONS
253	Clinical Efficacy of Clozapine in Treatment-Refractory Schizophrenia: An Overview. British Journal of Psychiatry, 1992, 160, 41-45.	2.8	147
254	The Prevalence of Tardive Dyskinesia. Journal of Clinical Psychopharmacology, 1991, 11, 34-42.	1.4	113
255	Obstacles to Clinical Research and New Drug Development in Schizophrenia. Schizophrenia Bulletin, 1991, 17, 353-356.	4.3	8
256	Clozapine for the Treatment-Resistant Schizophrenic. Archives of General Psychiatry, 1988, 45, 789.	12.3	3,867
257	Research Diagnoses for Tardive Dyskinesia. Archives of General Psychiatry, 1982, 39, 486.	12.3	738
258	Prescribing clozapine in the UK: Quality improvement issues identified by clinical audit. Journal of Psychopharmacology, 0, , 026988112211040.	4.0	1